We support the development of targeted radiotherapies and complex pharmacology programs with robust in vivo models, imaging, and data that reduce uncertainty at critical funding and development milestones.
Preparing for series A/B
Advancing pharmacology programs
Progressing from candidate to clinic
We support the development of targeted radiotherapies and complex pharmacology programs with robust in vivo models, imaging, and data that reduce uncertainty at critical funding and development milestones.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Insights into preclinical study design for inflammatory gut disease, covering acute vs chronic models, dosing strategies, and clinically relevant endpoints.
Insights into preclinical study design for inflammatory gut disease, covering acute vs chronic models, dosing strategies, and clinically relevant endpoints.
Insights into preclinical study design for inflammatory gut disease, covering acute vs chronic models, dosing strategies, and clinically relevant endpoints.
![[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach.](https://www.oncodesign-service.com/wp-content/uploads/2022/11/Scientific_publication_AdobeStock_111385963-374-374-scaled-1-1024x1024.png)
Insights into preclinical study design for inflammatory gut disease, covering acute vs chronic models, dosing strategies, and clinically relevant endpoints.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
